Extrapyramidal Symptoms (EPS): Definition, Affected Populations, and Pathophysiology
Extrapyramidal symptoms (EPS) are drug-induced movement disorders caused by dopamine receptor blockade in the basal ganglia, primarily affecting psychiatric patients treated with antipsychotic medications, particularly those receiving high-potency conventional agents like haloperidol. 1
What Are Extrapyramidal Symptoms?
EPS encompass four distinct categories of involuntary movement disorders that occur as adverse effects of antipsychotic medications 1:
Acute EPS (occurring during initial treatment phases):
Dystonia: Sudden spastic contraction of distinct muscle groups, often affecting the neck, eyes (oculogyric crisis), or torso 1. Laryngospasm represents a life-threatening variant that can present as choking sensation, difficulty breathing, or stridor 2.
Drug-induced Parkinsonism: Symptoms mimicking Parkinson's disease including bradykinesia (slowed movement), tremors, and rigidity 1. This can be difficult to differentiate from negative symptoms of schizophrenia or, in severe cases, catatonia 1.
Akathisia: A subjective sense of severe restlessness frequently manifesting as pacing or physical agitation 1. This is commonly misinterpreted as psychotic agitation or anxiety and represents a major cause of medication noncompliance 1.
Tardive Syndromes (occurring with long-term use):
- Tardive Dyskinesia (TD): Involuntary movement disorder consisting of athetoid or choreic movements, typically in the orofacial region (blinking, grimacing, chewing, tongue movements), but can affect any body part including extremities and trunk 1, 2. As many as 50% of youth receiving neuroleptics may experience some form of tardive or withdrawal dyskinesia 1.
Which Psychiatric Patients Experience EPS?
Primary Risk Groups:
Patients with schizophrenia and other psychotic disorders represent the largest population experiencing EPS, as they are the primary recipients of antipsychotic therapy 1. The pooled prevalence of antipsychotic-induced EPS is approximately 31-37% among all patients taking antipsychotics 3.
Specific Prevalence by EPS Type:
- Parkinsonism: 20% of patients on antipsychotics 3
- Akathisia: 11% of patients on antipsychotics 3
- Tardive dyskinesia: 7% of patients on antipsychotics 3
High-Risk Patient Characteristics:
Children and adolescents are at higher risk for EPS than adults 1. Specific risk factors include 1:
- Young age
- Male gender (particularly for dystonia)
- Use of high-potency conventional antipsychotics (e.g., haloperidol)
- Longer duration of illness 4
- Polypharmacy with antipsychotics 4
Additional Affected Populations:
- Patients with bipolar disorder receiving antipsychotic treatment 5
- Patients with mood disorders with psychotic features 5
- Elderly patients with dementia prescribed antipsychotics 2
- Substance abusers: Both those with and without schizophrenia show increased EPS, with cocaine and alcohol abuse/dependence increasing parkinsonism, and alcohol and cannabis abuse/dependence increasing akathisia 6
Pathophysiology of EPS
Primary Mechanism - Dopamine Receptor Blockade:
The fundamental pathophysiologic mechanism underlying EPS is excessive blockade of dopamine D2 receptors in the nigrostriatal pathway of the basal ganglia 1, 4. The side-effect profile of an antipsychotic agent relates directly to its degree of dopamine receptor blockade 1.
Specific Pathophysiologic Mechanisms by EPS Type:
High-potency agents (e.g., haloperidol) produce more EPS because they cause greater dopamine receptor blockade, whereas low-potency agents (e.g., thioridazine, chlorpromazine) have more anticholinergic side effects 1.
Acute dystonia, parkinsonism, and akathisia: Result from antidopaminergic effects causing a deficiency of dopaminergic activity in the central nervous system 2, 7. This creates an imbalance between dopaminergic and cholinergic neurotransmission in the basal ganglia 1.
Tardive dyskinesia: Associated with long-term dopamine receptor blockade, potentially involving dopamine receptor supersensitivity or other compensatory mechanisms that develop over time 1, 8.
Risk Factor Correlation:
Antipsychotics with high D2 receptor antagonistic effect and longer illness duration are independent risk factors for EPS development 4. The severity of various EPS types correlates significantly with psychiatric symptoms: parkinsonism correlates with negative symptoms and general psychopathology, while akathisia correlates with positive symptoms, general psychopathology, and depressive symptoms 4.
Clinical Significance:
The occurrence of EPS is associated with poor treatment outcomes in schizophrenia, with EPS patients showing significantly higher negative symptom scores, general psychopathological scores, and depressive symptom scores compared to non-EPS patients 4. EPS represents a common reason for medication noncompliance, which increases relapse risk and greater morbidity 1.